NYSA PHARMA CONSULTING LTD
Company number 11671321 · Active
NYSA PHARMA CONSULTING LTD is a private limited company registered in GLOUCESTER, United Kingdom, incorporated on 12 Nov 2018. Its registered activity is management consultancy activities other than financial management. Its latest published accounts for the period ending 30 Nov 2025 show equity of £113k, total assets of £113k. It has filed 7 sets of accounts, 1 of them after the deadline. Our model estimates a 0.00 % probability that it becomes insolvent within 12 months, 0.0 times the average for active companies (low risk).
Insolvency risk, next 12 months
Higher than 0 % of active companies in the United Kingdom. 0.0× the average annual insolvency rate (0.12 %).
Raises the risk
Lowers the risk
Each factor compares companies in the same group (for example the same age band) with the average. The score is a statistical estimate from public data (model AUC 0.99, trained 8 Nov 2026), not a credit rating. How it works.
Company details
- Company number
- 11671321 · official register
- Status
- Active
- Legal form
- Private Limited Company
- Incorporated
- 12 Nov 2018 (8 years)
- Registered address
- GL4 5DG GLOUCESTER
- Postcode area
- Gloucester
- Activity
- 70229 Management consultancy activities other than financial management
- Industry
- Head offices; management consultancy
- Accounts overdue
- No
Insolvency and register events
No insolvency or liquidation events on record.
Annual accounts GBP
| Period end | Published | Turnover | Result | Equity | Total assets | Current liabilities | Cash | Employees |
|---|---|---|---|---|---|---|---|---|
| 30 Nov 2025 | 25 Aug 2026 | – | – | £113k | £113k | £0 | – | 0 |
| 30 Nov 2024 | 15 Aug 2025 | – | – | £113k | £113k | £0 | – | 0 |
| 30 Nov 2023 | 15 Aug 2024 | – | – | £113k | £113k | £0 | – | 0 |
| 30 Nov 2022 | 15 Aug 2023 | – | – | £113k | £124k | £11k | – | 0 |
| 30 Nov 2021 | 15 Aug 2022 | – | – | £97k | £106k | £9,478 | – | 0 |
| 30 Nov 2020 | 15 Aug 2021 | – | – | £71k | £72k | £520 | – | 0 |
| 30 Nov 2019 | 15 Nov 2020 | – | – | £71k | £98k | £27k | – | 0 |
As published. Small companies often file a balance sheet only, so turnover and result can be missing.
Similar companies in Gloucester
- &GO&CO LTD CHELTENHAM
- 11 INVESTMENTS LIMITED CHELTENHAM
- 2020CONSULT LTD CHELTENHAM
- 2B INSPIRED LIMITED COWLEY
- 360 STRATEGY CONSULTING LTD CHELTENHAM
- 39A CONSULTING LIMITED WOTTON UNDER EDGE
- 3C BUSINESS ASSOCIATES LIMITED STONEHOUSE
- 3C MARKETING LIMITED CHELTENHAM
- 3D PROJECTS (UK) LIMITED WOTTON-UNDER-EDGE
- 3SIXTYHSE LTD GLOUCESTER
- 3V NATURAL FOODS LIMITED GLOUCESTER
- 4 QUADRANT COACHING LTD CIRENCESTER
Questions about NYSA PHARMA CONSULTING LTD
What is the company number of NYSA PHARMA CONSULTING LTD?
NYSA PHARMA CONSULTING LTD is registered under company number 11671321 in the official register of United Kingdom. View it at the official register.
Is NYSA PHARMA CONSULTING LTD still active?
Yes. NYSA PHARMA CONSULTING LTD is registered as active (status: Active).
Has NYSA PHARMA CONSULTING LTD gone bankrupt or into insolvency?
No insolvency, bankruptcy or administration is recorded for NYSA PHARMA CONSULTING LTD in the official data.
How likely is NYSA PHARMA CONSULTING LTD to become insolvent?
Our model estimates a 0.00 % probability that NYSA PHARMA CONSULTING LTD becomes insolvent within the next 12 months (low risk). That is higher than 0 % of active companies in the United Kingdom.
When was NYSA PHARMA CONSULTING LTD founded?
NYSA PHARMA CONSULTING LTD was incorporated on 12 Nov 2018.
Where is NYSA PHARMA CONSULTING LTD registered?
NYSA PHARMA CONSULTING LTD's registered address is in GL4 5DG GLOUCESTER (Gloucester), United Kingdom.
What do the latest accounts of NYSA PHARMA CONSULTING LTD show?
The latest published accounts (period ending 30 Nov 2025) show equity of £113k, total assets of £113k, 0 employees.
Data: Companies House – Free Company Data Product, Accounts Data Product, Public Data API (Contains public sector information licensed under the Open Government Licence v3.0.). Last updated 8 Nov 2026.